Literature DB >> 25034283

The inflammasome in liver injury and non-alcoholic fatty liver disease.

Wajahat Zafar Mehal1.   

Abstract

The liver possesses a strong inflammatory response, as seen experimentally and clinically with liver inflammation due to toxic and metabolic stress, sepsis and ischemia. Initiation of this inflammatory response requires the interaction of two types of extracellular signals which collectively upregulate and activate a cytosolic molecular complex termed the inflammasome. Signal 1 is via activation of pattern recognition receptors, and signal 2 is delivered by diverse stimuli including particulates and adenosine triphosphate. The common end result of inflammasome activation is the activation of the protease caspase-1 with release of active interleukin-1β. The inflammasome is important in a wide range of conditions including alcoholic and non-alcoholic steatohepatitis. Kupffer cells are known to be important, but the consequences of inflammasome activation in other hepatic immune cells have not been well characterized. The inflammasome pathway is also known to be required for a full fibrotic response, as demonstrated by reduced lung, skin and liver fibrosis in inflammasome-deficient mice. Identification of the inflammasome machinery has opened up novel therapeutic avenues by the use of antagonists for Toll-like receptors as well as the adenosine triphosphate receptor P2X7, and the interleukin-1 receptor. There is now great interest in how inflammasome pathways are regulated. The initial challenge is to understand how an acute inflammatory response is sustained. This is a significant issue as the known stimuli result in an acute response that is self-limited to under 24 h. This suggests that there are significant regulators which allow sustained inflammasome activation in conditions such as non-alcoholic steatohepatitis and alcoholic hepatitis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25034283     DOI: 10.1159/000360495

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  30 in total

1.  Purinergic receptor X7 mediates leptin induced GLUT4 function in stellate cells in nonalcoholic steatohepatitis.

Authors:  Varun Chandrashekaran; Suvarthi Das; Ratanesh Kumar Seth; Diptadip Dattaroy; Firas Alhasson; Gregory Michelotti; Mitzi Nagarkatti; Prakash Nagarkatti; Anna Mae Diehl; Saurabh Chatterjee
Journal:  Biochim Biophys Acta       Date:  2015-10-22

2.  Aquaporin-3 is involved in NLRP3-inflammasome activation contributing to the setting of inflammatory response.

Authors:  Pablo Pelegrín; Graça Soveral; Inês Vieira da Silva; Carlos Cardoso; Helios Martínez-Banaclocha; Angela Casini
Journal:  Cell Mol Life Sci       Date:  2020-11-24       Impact factor: 9.261

3.  Sparstolonin B attenuates early liver inflammation in experimental NASH by modulating TLR4 trafficking in lipid rafts via NADPH oxidase activation.

Authors:  Diptadip Dattaroy; Ratanesh Kumar Seth; Suvarthi Das; Firas Alhasson; Varun Chandrashekaran; Gregory Michelotti; Daping Fan; Mitzi Nagarkatti; Prakash Nagarkatti; Anna Mae Diehl; Saurabh Chatterjee
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-12-30       Impact factor: 4.052

4.  Digoxin improves steatohepatitis with differential involvement of liver cell subsets in mice through inhibition of PKM2 transactivation.

Authors:  Peng Zhao; Sheng-Na Han; Suyavaran Arumugam; Muhammad Nadeem Yousaf; Yanqin Qin; Joy X Jiang; Natalie Julia Torok; Yonglin Chen; Mohd Salah Mankash; Junbao Liu; Jiansheng Li; Yasuko Iwakiri; Xinshou Ouyang
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-08-14       Impact factor: 4.052

Review 5.  IL-1 Family Cytokine Pathways Underlying NAFLD: Towards New Treatment Strategies.

Authors:  Andreea-Manuela Mirea; Cees J Tack; Triantafyllos Chavakis; Leo A B Joosten; Erik J M Toonen
Journal:  Trends Mol Med       Date:  2018-04-14       Impact factor: 11.951

Review 6.  Inflammasome activation and function in liver disease.

Authors:  Gyongyi Szabo; Jan Petrasek
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-06-09       Impact factor: 46.802

7.  Emerging roles of myeloid derived suppressor cells in hepatic inflammation and fibrosis.

Authors:  Linda Hammerich; Frank Tacke
Journal:  World J Gastrointest Pathophysiol       Date:  2015-08-15

8.  NLRP3 inhibitor glibenclamide attenuates high-fat diet and streptozotocin-induced non-alcoholic fatty liver disease in rat: studies on oxidative stress, inflammation, DNA damage and insulin signalling pathway.

Authors:  Durgesh Kumar Dwivedi; G B Jena
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-12-13       Impact factor: 3.000

Review 9.  Innate Immunity and Inflammation in NAFLD/NASH.

Authors:  Marco Arrese; Daniel Cabrera; Alexis M Kalergis; Ariel E Feldstein
Journal:  Dig Dis Sci       Date:  2016-02-03       Impact factor: 3.199

Review 10.  The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH).

Authors:  Marina Nati; David Haddad; Andreas L Birkenfeld; Christian A Koch; Triantafyllos Chavakis; Antonios Chatzigeorgiou
Journal:  Rev Endocr Metab Disord       Date:  2016-03       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.